RVL Pharmaceuticals plc (NASDAQ: RVLP) Presents Achievements, Goals at H.C. Wainwright 25th Annual Global Investment Conference in New York City
- RVL Pharmaceuticals CEO Brian Markison participated in a fireside chat and hosted one-on-one investor meetings during the conference
- The company’s primary focus is the commercialization of UPNEEQ(R), which is available by prescription for treating acquired blepharoptosis or low-lying eyelids in adults
- The global medical aesthetics market was estimated at $13.9 billion in 2022 and is expected to reach $23.4 billion by 2027, growing at a CAGR of 11%
- RVL Pharmaceuticals markets UPNEEQ(R) to HCPs and plans to launch a direct-to-consumer campaign later this year
RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas, recently presented at the H.C. Wainwright 25th Annual Global Investment Conference. The conference was held virtually and in person on September 11-13, 2023, at the Lotte New York Palace Hotel in New York City.
The H.C. Wainwright 25th Annual Global Investment Conference is the premier event for companies and investors in life sciences, cryptocurrency, blockchain, fintech, metals, mining, technology, media, telecommunications, cleantech, and more. The three-day event was filled with leading industry keynote speakers, presenting companies, investor one-on-one meetings, networking opportunities, and evening entertainment.
RVL Pharmaceuticals CEO Brian Markison participated in a fireside chat and hosted one-on-one investor meetings during this year’s H.C. Wainwright conference. The company’s primary focus is the commercialization of UPNEEQ(R), which is available by prescription for treating acquired blepharoptosis or low-lying eyelids in adults. UPNEEQ(R) is a once-daily eye drop shown in clinical trials to result in an average lift of one-millimeter to the upper eyelid, improving appearance and the superior visual field in patients with a functional deficit.
Patients eligible for treatment with UPNEEQ(R) include adults with droopy or low-lying eyelids, the majority of whom are females. Although the exact prevalence of acquired ptosis is unknown, RVL Pharmaceuticals believes it to be a common age-related condition.
The global medical aesthetics market revenue was estimated at $13.9 billion in 2022. It is expected to grow at a CAGR of 11%, reaching $23.4 billion by 2027. (https://nnw.fm/dAtxc ). The market’s expansion is believed to be due to factors such as the rising popularity of minimally invasive and non-invasive aesthetic procedures, the rising popularity of aesthetic procedures among older patients, greater accessibility to technologically advanced and user-friendly products, and the rise in demand for aesthetic treatments among the male population.
Access to UPNEEQ(R) is supported by the company’s Elevate eCommerce platform, launched in July 2023. The Elevate platform enables patient subscription ordering across channels, including HCP direct practices, HCP virtual practices, and RVL pharmacy eye care patients. The platform enhances patient retention by allowing for refills to be fulfilled by RVL Pharmacy and delivered directly to the patient’s home. At the same time, HCPs continue to share customer refills’ value. The pharmacy also offers auto-replenishment for HCPs that dispense UPNEEQ(R) through their practice.
By participating in the H.C. Wainwright conference, RVL Pharmaceuticals was able to present the benefits and significance of UPNEEQ(R) to other public companies, industry executives, business development executives, institutional investors, private equity firms, and venture capitalists.
For more information, visit the company’s website at www.RVLPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to RVLP are available in the company’s newsroom at https://nnw.fm/RVLP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- RVL Pharmaceuticals CEO Brian Markison participated in a fireside chat and hosted one-on-one investor meetings during the conference
- The company’s primary focus is the commercialization of UPNEEQ(R), which is available by prescription for treating acquired blepharoptosis or low-lying eyelids in adults
- The global medical aesthetics market was estimated at $13.9 billion in 2022 and is expected to reach $23.4 billion by 2027, growing at a CAGR of 11%
- RVL Pharmaceuticals markets UPNEEQ(R) to HCPs and plans to launch a direct-to-consumer campaign later this year
RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas, recently presented at the H.C. Wainwright 25th Annual Global Investment Conference. The conference was held virtually and in person on September 11-13, 2023, at the Lotte New York Palace Hotel in New York City.
The H.C. Wainwright 25th Annual Global Investment Conference is the premier event for companies and investors in life sciences, cryptocurrency, blockchain, fintech, metals, mining, technology, media, telecommunications, cleantech, and more. The three-day event was filled with leading industry keynote speakers, presenting companies, investor one-on-one meetings, networking opportunities, and evening entertainment.
RVL Pharmaceuticals CEO Brian Markison participated in a fireside chat and hosted one-on-one investor meetings during this year’s H.C. Wainwright conference. The company’s primary focus is the commercialization of UPNEEQ(R), which is available by prescription for treating acquired blepharoptosis or low-lying eyelids in adults. UPNEEQ(R) is a once-daily eye drop shown in clinical trials to result in an average lift of one-millimeter to the upper eyelid, improving appearance and the superior visual field in patients with a functional deficit.
Patients eligible for treatment with UPNEEQ(R) include adults with droopy or low-lying eyelids, the majority of whom are females. Although the exact prevalence of acquired ptosis is unknown, RVL Pharmaceuticals believes it to be a common age-related condition.
The global medical aesthetics market revenue was estimated at $13.9 billion in 2022. It is expected to grow at a CAGR of 11%, reaching $23.4 billion by 2027. (https://nnw.fm/dAtxc ). The market’s expansion is believed to be due to factors such as the rising popularity of minimally invasive and non-invasive aesthetic procedures, the rising popularity of aesthetic procedures among older patients, greater accessibility to technologically advanced and user-friendly products, and the rise in demand for aesthetic treatments among the male population.
Access to UPNEEQ(R) is supported by the company’s Elevate eCommerce platform, launched in July 2023. The Elevate platform enables patient subscription ordering across channels, including HCP direct practices, HCP virtual practices, and RVL pharmacy eye care patients. The platform enhances patient retention by allowing for refills to be fulfilled by RVL Pharmacy and delivered directly to the patient’s home. At the same time, HCPs continue to share customer refills’ value. The pharmacy also offers auto-replenishment for HCPs that dispense UPNEEQ(R) through their practice.
By participating in the H.C. Wainwright conference, RVL Pharmaceuticals was able to present the benefits and significance of UPNEEQ(R) to other public companies, industry executives, business development executives, institutional investors, private equity firms, and venture capitalists.
For more information, visit the company’s website at www.RVLPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to RVLP are available in the company’s newsroom at https://nnw.fm/RVLP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
